ACR Gout Guidelines 2026: What Changed and Why It Matters

Key Takeaways

• The 2020 ACR guidelines introduced a treat-to-target approach: aim for serum urate below 6 mg/dL, or below 5 mg/dL if tophi are present (ACR, 2020)
• Urate-lowering therapy is now recommended after just 2+ flares per year, even if they occur in different years
• Anti-inflammatory prophylaxis for 3-6 months when starting ULT is strongly recommended to prevent mobilization flares
• Allopurinol should start at 50-100 mg/day and titrate monthly, not at a fixed "standard" dose
• Roughly 37% of gout patients remain above their urate target despite being on ULT, largely due to undertitration (Singh et al., Arthritis Care and Research, 2016)

The American College of Rheumatology released its 2020 gout management guidelines after a decade without a major update. That's a long gap for a condition affecting more than 9.2 million adults in the United States (CDC, 2023). The new guidelines didn't just tweak dosing numbers. They shifted the entire philosophy of care, from waiting for symptoms to get bad enough to act, toward a structured treat-to-target approach.

If you or someone you love has been diagnosed with gout, understanding these changes can make a real difference in outcomes. This article walks through each major recommendation, explains the reasoning behind it, and flags what you need to discuss with your rheumatologist.

What Is the Treat-to-Target Approach and Why Did the ACR Adopt It?

The 2020 ACR guidelines are built around a treat-to-target (T2T) strategy, meaning treatment decisions are driven by hitting a measurable lab number, not just managing symptoms. The target is serum urate below 6 mg/dL for most patients, and below 5 mg/dL for those with tophi (ACR, 2020). This is a meaningful shift from older symptom-based care, where many clinicians simply prescribed a standard allopurinol dose and moved on.

Why does the number matter so much? Uric acid crystals dissolve when serum urate stays consistently below 6.8 mg/dL, the saturation point. But just getting under saturation isn't enough to clear existing crystal deposits from joints. Keeping levels at or below 6 mg/dL provides a buffer and accelerates crystal dissolution over time.

Many patients feel fine between flares and assume their gout is "controlled." In reality, uric acid crystals can silently accumulate in joints and soft tissue for years before causing visible damage or a noticeable flare. The treat-to-target model exists precisely because symptom absence isn't the same as disease control.

Research published in Arthritis Care and Research found that approximately 37% of patients on urate-lowering therapy still don't reach their serum urate target, most often because their dose was never titrated upward (Singh et al., 2016).

Who Should Start Urate-Lowering Therapy?

The 2020 ACR guidelines expanded the indications for urate-lowering therapy (ULT). ULT is strongly recommended for patients who have 2 or more flares per year, even if those flares happen in different calendar years (ACR, 2020).

Additional indications include:

• Presence of one or more tophi
• Gout-related joint damage visible on imaging
• Chronic kidney disease stage 3 or worse
• First flare with a serum urate level at or above 9 mg/dL

The guidelines also conditionally recommend ULT after a first flare in patients with CKD, urolithiasis, or very high baseline serum urate. The intent is to intervene before repeated crystal deposition causes irreversible structural joint damage.

Patients frequently report being told to "wait and see" after a first flare. Under the 2020 framework, that approach is appropriate only for low-risk patients with normal urate levels. For anyone with CKD or urate above 9 mg/dL at first flare, starting ULT right away is now the evidence-based choice.

How Should Allopurinol Be Started and Titrated?

Allopurinol remains the preferred first-line ULT, but the way it's started has changed significantly. The 2020 guidelines recommend beginning at a low dose of 50-100 mg per day, not the 300 mg "standard dose" that was common practice for decades (ACR, 2020). The dose should then be increased monthly until the serum urate target is reached.

Rapid lowering of urate mobilizes crystals from soft tissues into the joint space, which can actually trigger a flare. Slow titration reduces that risk and allows time to catch early signs of allopurinol hypersensitivity syndrome.

For patients with chronic kidney disease, start at 50 mg daily in CKD stages 3-5, then titrate upward gradually. The 2020 guidelines state that doses above the renal-adjusted maximum are acceptable if needed to reach the urate target, provided the patient is monitored closely.

Febuxostat is an alternative for patients who can't tolerate allopurinol, but note the FDA black box warning: febuxostat carries a higher risk of cardiovascular mortality in patients with established cardiovascular disease.

Why Anti-Inflammatory Prophylaxis Is Critical When Starting ULT

When starting or escalating ULT, patients should take low-dose colchicine (0.6 mg once or twice daily) or a low-dose NSAID for 3 to 6 months to prevent mobilization flares (ACR, 2020).

About 30% of patients starting ULT experience increased flare frequency in the first few months (Abhishek et al., Arthritis Research and Therapy, 2017). Without prophylaxis, many patients interpret that surge as the medication "making things worse" and stop taking it. That's exactly the opposite of what should happen.

Low-dose colchicine is preferred when tolerated. For patients who can't tolerate either colchicine or NSAIDs, low-dose prednisone is an acceptable fallback. The guidelines don't support stopping ULT during a flare; continuing therapy while treating the acute flare is now the recommended approach.

Adherence to ULT is a documented challenge. Studies show that fewer than half of gout patients remain on ULT after one year (Sarawate et al., Journal of Clinical Rheumatology, 2006). Prophylaxis significantly improves early adherence by reducing the flare burden that drives patients to quit.

Second-Line and Escalation Options

When allopurinol at maximum tolerated dose doesn't achieve the serum urate target, the 2020 guidelines outline a clear escalation path. Uricosuric agents like probenecid can be used as monotherapy or added to allopurinol when partial response is insufficient. They're less effective in CKD and should not be used in patients with urolithiasis.

Pegloticase (Krystexxa) is reserved for refractory tophaceous gout that hasn't responded to other ULT. It's administered by IV infusion every two weeks. Roughly 40-50% of patients achieve and maintain target urate levels at 6 months in clinical trials (Sundy et al., JAMA, 2011). Infusion reactions are common, and patients who lose response should stop infusions promptly to avoid anaphylaxis risk.

How Should Acute Gout Flares Be Treated?

For acute flares, the 2020 guidelines recommend starting treatment as early as possible, ideally within 12 to 24 hours of onset (ACR, 2020). The three first-line options are low-dose colchicine, NSAIDs, and oral corticosteroids.

Low-dose colchicine (1.2 mg followed by 0.6 mg one hour later) works best when started early and has a more favorable side effect profile than high-dose regimens (NEJM, 2010). Oral prednisone (30-40 mg/day for 3-5 days) is preferred when colchicine and NSAIDs are both contraindicated.

Ice applied to the affected joint is explicitly recognized as an evidence-based adjunct that reduces pain without significant risk. IL-1 inhibitors like anakinra or canakinumab offer an alternative for patients who can't tolerate standard therapy.

What the 2020 Guidelines Say About Lifestyle Changes

The guidelines strongly recommend weight loss for patients who are overweight, reducing alcohol intake (especially beer and spirits), and avoiding high-fructose corn syrup (ACR, 2020). The DASH diet is conditionally recommended for overall cardiovascular and metabolic benefit.

One underappreciated finding: a strict low-purine diet is not strongly recommended as a primary management tool. Even a very restrictive low-purine diet typically lowers serum urate by only 1-2 mg/dL, whereas allopurinol at therapeutic doses can lower it by 4-8 mg/dL. Medication does the heavy lifting.

Medication Interactions Every Gout Patient Should Know About

Thiazide and loop diuretics raise serum urate and are a common hidden cause of undertreated gout in patients with hypertension or heart failure (ACR, 2020). Losartan has a mild uricosuric effect and is worth considering over other antihypertensives when patients have both conditions.

Low-dose aspirin does raise urate modestly. However, the guidelines recommend continuing it if there's a cardiovascular indication. Stopping aspirin to manage gout is not appropriate when the cardiovascular risk is real.

Colchicine interacts significantly with CYP3A4 and P-glycoprotein inhibitors, including clarithromycin and certain statins. Patients on multiple medications should review their full list with a pharmacist when starting colchicine.

Frequently Asked Questions

Do I need to take urate-lowering therapy forever?

For most patients with recurrent gout, yes. The 2020 ACR guidelines treat gout as a chronic disease requiring long-term management. Once ULT is started and the urate target is reached, stopping medication typically leads to urate levels rising again and flares returning. A rheumatologist can review whether discontinuation is appropriate after a prolonged period of stable, low urate levels.

Can I stop allopurinol during a flare?

No. The 2020 guidelines specifically recommend continuing ULT during acute flares. Stopping and restarting allopurinol causes additional urate fluctuations, which may prolong or worsen the flare. Treat the acute attack with colchicine, NSAIDs, or steroids while keeping the allopurinol dose steady.

What serum urate level should I aim for?

The 2020 guidelines set the target below 6 mg/dL for most patients. If you have tophi, the target is stricter: below 5 mg/dL. Getting tested every 2-4 weeks while titrating, then every 6 months once stable, is the recommended monitoring schedule (ACR, 2020).

Why do I get more flares when I first start allopurinol?

Starting ULT mobilizes uric acid crystals from joints and soft tissue as they begin to dissolve. This temporary crystal shedding triggers flares. It's expected and doesn't mean allopurinol is making things worse. Anti-inflammatory prophylaxis with low-dose colchicine or an NSAID for the first 3-6 months significantly reduces this risk.

Putting It All Together

The 2020 ACR gout guidelines mark a real shift toward treating gout with the same rigor applied to other chronic diseases. Treat-to-target, consistent monitoring, proper titration, prophylaxis, and a clear escalation pathway replace the older approach that left too many patients with uncontrolled disease and progressive joint damage.

If you're currently on gout medication, ask your doctor whether your serum urate has been measured recently and whether it's below 6 mg/dL. If it's not, your regimen may need adjustment. If you've had 2 or more flares in recent years but haven't started ULT, that's worth a conversation with a rheumatologist.

Tracking your flares, your food choices, and your urate trends between appointments is where a tool like GoutSnap can help. Available for iOS and Android.